Action ZVRA ZEVRA THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Zevra Therapeutics, Inc.

Actions

ZVRA

US4884452065

Temps réel estimé Cboe BZX
Autres places de cotation
 16:34:51 27/06/2024 		Varia. 5j. Varia. 1 janv.
4,655 USD +0,11% Graphique intraday de Zevra Therapeutics, Inc. +6,88% -28,85%
25/06 Zevra Therapeutics, Inc. élargit son équipe de direction CI
04/06 Zevra Therapeutics dépose une déclaration d'enregistrement mixte de 350 millions de dollars ; les actions chutent après les heures d'ouverture MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Zevra Therapeutics Expands Executive Leadership Team
AQ
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
PR
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
AQ
Zevra Therapeutics to Participate at Upcoming Investor Events
AQ
Zevra Therapeutics: Q1 Earnings Snapshot
AQ
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
PR
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
AQ
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
PR
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
PR
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
PR
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
AQ
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
AQ
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
AQ
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ZVRA
  4. Actualités Zevra Therapeutics, Inc.
  5. Communiqués